SynthesisDrug design, development and therapy2018
Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.
Synthesis in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- Adalimumab biosimilars compared to originator: impact on uveitic macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study.Children (Basel, Switzerland) · 2026Article
- Vogt-Koyanagi-Harada (VKH)-What Do We Know About the Disease, and Can We Recognize It?Diagnostics (Basel, Switzerland) · 2026Article
- Beyond the joints: mechanistic insights and multidisciplinary strategies for spondyloarthritis-associated uveitis.Frontiers in immunology · 2025Review
- IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis.Frontiers in immunology · 2025Article
- Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies.Antibodies (Basel, Switzerland) · 2024Review
- Uveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review.Children (Basel, Switzerland) · 2024Review
- Diagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review (2018-2023).Journal of clinical medicine · 2024Review
- Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study.Eye (London, England) · 2024Article
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Article
- Ocular Manifestations of Spondyloarthritis.Mediterranean journal of rheumatology · 2023Review
- Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.Ophthalmology and therapy · 2023Article
- Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.Acta ophthalmologica · 2022Article
- The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.Yonsei medical journal · 2021Observational
- TNF-α in Uveitis: From Bench to Clinic.Frontiers in pharmacology · 2021Review
- Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo summarize updated evidences on the efficacy and safety of adalimumab (ADA) in the treatment of patients with non-infectious uveitis. PATIENTS AND
methodsA systematic search between January 2000 and September 2017 was conducted using PubMed, Embase, and Cochrane libraries. We investigated control of inflammation, improvement of visual acuity (VA), corticosteroid-sparing effect, and adverse events (AEs) or serious adverse events.
resultsThree randomized clinical trials (RCTs) and 20 non-RCTs were included and analyzed. The pooled proportions of inflammation control were 74% (95% CI 64%-82%) and 79% (95% CI 69%-87%) in groups of ≤6- and ≥12-months follow-up durations. No significant difference was found between the two groups (
conclusionThe current review provided evidences that ADA might be a promising choice in reducing inflammatory activity, gaining VA, and sparing corticosteroid use with minor AEs when applied in treating non-infectious uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.